These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 20800067)
21. Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure. Rengo G; Leosco D; Zincarelli C; Marchese M; Corbi G; Liccardo D; Filippelli A; Ferrara N; Lisanti MP; Koch WJ; Lymperopoulos A Am J Physiol Heart Circ Physiol; 2010 Jun; 298(6):H2032-8. PubMed ID: 20304818 [TBL] [Abstract][Full Text] [Related]
22. betaARKct: a therapeutic approach for improved adrenergic signaling and function in heart disease. Brinks H; Koch WJ J Cardiovasc Transl Res; 2010 Oct; 3(5):499-506. PubMed ID: 20623214 [TBL] [Abstract][Full Text] [Related]
23. GRK2 as a therapeutic target for heart failure. Cannavo A; Komici K; Bencivenga L; D'amico ML; Gambino G; Liccardo D; Ferrara N; Rengo G Expert Opin Ther Targets; 2018 Jan; 22(1):75-83. PubMed ID: 29166798 [TBL] [Abstract][Full Text] [Related]
24. G-protein-coupled receptor kinase 2-mediated desensitization of adiponectin receptor 1 in failing heart. Wang Y; Gao E; Lau WB; Wang Y; Liu G; Li JJ; Wang X; Yuan Y; Koch WJ; Ma XL Circulation; 2015 Apr; 131(16):1392-404. PubMed ID: 25696921 [TBL] [Abstract][Full Text] [Related]
25. Myocardial G protein receptor-coupled kinase expression correlates with functional parameters and clinical severity in advanced heart failure. Agüero J; Almenar L; Montó F; Oliver E; Sánchez-Lázaro I; Vicente D; Martínez-Dolz L; D'Ocon P; Rueda J; Salvador A J Card Fail; 2012 Jan; 18(1):53-61. PubMed ID: 22196842 [TBL] [Abstract][Full Text] [Related]
27. Pharmacological inhibition of GRK2 improves cardiac metabolism and function in experimental heart failure. Ciccarelli M; Sorriento D; Fiordelisi A; Gambardella J; Franco A; Del Giudice C; Sala M; Monti MG; Bertamino A; Campiglia P; Oliveti M; Poggio P; Trinchese G; Cavaliere G; Cipolletta E; Mollica MP; Bonaduce D; Trimarco B; Iaccarino G ESC Heart Fail; 2020 Aug; 7(4):1571-1584. PubMed ID: 32352228 [TBL] [Abstract][Full Text] [Related]
28. The cellular and physiologic effects of beta blockers in heart failure. Sabbah HN Clin Cardiol; 1999 Oct; 22 Suppl 5():V16-20. PubMed ID: 10526699 [TBL] [Abstract][Full Text] [Related]
29. Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved beta-adrenergic signaling after mechanical unloading. Hata JA; Williams ML; Schroder JN; Lima B; Keys JR; Blaxall BC; Petrofski JA; Jakoi A; Milano CA; Koch WJ J Card Fail; 2006 Jun; 12(5):360-8. PubMed ID: 16762799 [TBL] [Abstract][Full Text] [Related]
30. (-)-Epigallocatechin-3-gallate, the major green tea catechin, regulates the desensitization of β1 adrenoceptor via GRK2 in experimental heart failure. Zhang Q; Hu L; Chen L; Li H; Wu J; Liu W; Zhang M; Yan G Inflammopharmacology; 2018 Aug; 26(4):1081-1091. PubMed ID: 29247373 [TBL] [Abstract][Full Text] [Related]
31. GRK2 in cardiovascular disease and its potential as a therapeutic target. Ferrero KM; Koch WJ J Mol Cell Cardiol; 2022 Nov; 172():14-23. PubMed ID: 35878706 [TBL] [Abstract][Full Text] [Related]
33. Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2) -adrenoceptor-catecholamine production axis in heart failure. Rengo G; Lymperopoulos A; Zincarelli C; Femminella G; Liccardo D; Pagano G; de Lucia C; Cannavo A; Gargiulo P; Ferrara N; Perrone Filardi P; Koch W; Leosco D Br J Pharmacol; 2012 Aug; 166(8):2430-40. PubMed ID: 22519418 [TBL] [Abstract][Full Text] [Related]
34. G protein-coupled receptor kinase 2: a link between myocardial contractile function and cardiac metabolism. Woodall MC; Ciccarelli M; Woodall BP; Koch WJ Circ Res; 2014 May; 114(10):1661-70. PubMed ID: 24812353 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice. Abd Alla J; Graemer M; Fu X; Quitterer U J Biol Chem; 2016 Feb; 291(6):2583-600. PubMed ID: 26670611 [TBL] [Abstract][Full Text] [Related]
36. Gene-mediated inhibition of the b-adrenergic receptor kinase: a new therapeutic strategy for heart failure. Tevaearai HT; Eckhart AD; Koch WJ Minerva Cardioangiol; 2001 Dec; 49(6):389-94. PubMed ID: 11733734 [TBL] [Abstract][Full Text] [Related]
37. The expanding GRK interactome: Implications in cardiovascular disease and potential for therapeutic development. Hullmann J; Traynham CJ; Coleman RC; Koch WJ Pharmacol Res; 2016 Aug; 110():52-64. PubMed ID: 27180008 [TBL] [Abstract][Full Text] [Related]
38. Cardiac progenitor cells engineered with βARKct have enhanced β-adrenergic tolerance. Khan M; Mohsin S; Toko H; Alkatib M; Nguyen J; Truffa S; Gude N; Chuprun K; Tilley DG; Koch WJ; Sussman MA Mol Ther; 2014 Jan; 22(1):178-85. PubMed ID: 24002692 [TBL] [Abstract][Full Text] [Related]
39. Cardiac resynchronization therapy restores sympathovagal balance in the failing heart by differential remodeling of cholinergic signaling. DeMazumder D; Kass DA; O'Rourke B; Tomaselli GF Circ Res; 2015 May; 116(10):1691-9. PubMed ID: 25733594 [TBL] [Abstract][Full Text] [Related]